Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muzaffar H Qazilbash

Showing results (91-100 of 188) with videos related to

Pageof 19
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 23, 2011
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of lifeGheath Alatrash, Marcos de Lima, Nelson Hamerschlak, et al.
Bone Marrow Transplantation|December 23, 2017
Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefitBrittany Knick Ragon, Rohtesh S Mehta, Alison M Gulbis, et al.
American Journal of Hematology|December 15, 2018
Long-term durable efficacy of autologous stem cell transplantation in POEMS syndromeNeeraj Y Saini, Romil D Patel, Ankur Varma, et al.
Haematologica|August 19, 2021
Melphalan dose intensity for autologous stem cell transplantation in multiple myelomaSamer A Srour, Denái R Milton, Qaiser Bashir, et al.
Transplantation and Cellular Therapy|July 28, 2022
Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor TransplantationRohtesh S Mehta, Rima M Saliba, Gabriela Rondon, et al.
Cancer|May 18, 2017
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myelomaLauren W Veltri, Denái R Milton, Ruby Delgado, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 26, 2015
Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell TransplantationRyan W Jacobs, Rima M Saliba, Koji Sasaki, et al.
American Journal of Hematology|May 14, 2022
Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myelomaAnita D'Souza, Ruta Brazauskas, Edward A Stadtmauer, et al.
Leukemia & Lymphoma|July 9, 2019
Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 yearsQaiser Bashir, Kamal Chamoun, Denái R Milton, et al.
Leukemia & Lymphoma|June 3, 2014
Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myelomaZartash Gul, Qaiser Bashir, Martin Cremer, et al.
Pageof 19

Showing results (91-100 of 188) with videos related to

Sort By:
Pageof 19
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 23, 2011
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of lifeGheath Alatrash, Marcos de Lima, Nelson Hamerschlak, et al.
Bone Marrow Transplantation|December 23, 2017
Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefitBrittany Knick Ragon, Rohtesh S Mehta, Alison M Gulbis, et al.
American Journal of Hematology|December 15, 2018
Long-term durable efficacy of autologous stem cell transplantation in POEMS syndromeNeeraj Y Saini, Romil D Patel, Ankur Varma, et al.
Haematologica|August 19, 2021
Melphalan dose intensity for autologous stem cell transplantation in multiple myelomaSamer A Srour, Denái R Milton, Qaiser Bashir, et al.
Transplantation and Cellular Therapy|July 28, 2022
Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor TransplantationRohtesh S Mehta, Rima M Saliba, Gabriela Rondon, et al.
Cancer|May 18, 2017
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myelomaLauren W Veltri, Denái R Milton, Ruby Delgado, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 26, 2015
Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell TransplantationRyan W Jacobs, Rima M Saliba, Koji Sasaki, et al.
American Journal of Hematology|May 14, 2022
Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myelomaAnita D'Souza, Ruta Brazauskas, Edward A Stadtmauer, et al.
Leukemia & Lymphoma|July 9, 2019
Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 yearsQaiser Bashir, Kamal Chamoun, Denái R Milton, et al.
Leukemia & Lymphoma|June 3, 2014
Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myelomaZartash Gul, Qaiser Bashir, Martin Cremer, et al.
Pageof 19